Today's Trend
Adicet Bio, Inc. (NASDAQ: ACET) is receiving a modestly favorable signal from updated analyst forecasts, although the company remains deeply unprofitable and the stock continues to carry substantial clinical-development risk.
- HC Wainwright materially improved its loss estimates for Adicet Bio. The firm now expects a loss of $2.05 per share in Q3 2026 versus a prior estimate of $2.93, a Q4 2026 loss of $2.12 versus $2.99 previously, and a full-year 2026 loss of $8.05 versus $11.58. The revised full-year outlook is also better than the current consensus loss estimate of $8.52, which may be supporting investor sentiment. Adicet Bio analyst estimates
- HC Wainwright projects further improvement in Adicet Bio’s results in 2027, forecasting a full-year loss of $7.67 per share. Its quarterly estimates range from a $2.19 loss in Q1 to a $1.78 loss in Q3, suggesting a gradual reduction in losses compared with 2026. Adicet Bio 2027 earnings estimates
- The company’s strong liquidity profile remains an important consideration: Adicet Bio has reported a quick and current ratio of 6.71 and debt-to-equity of 0.01. However, its market capitalization is only about $77 million, and the stock remains highly volatile, with a beta of 1.60.
- A report showing zero short interest as of August 11 is not useful for gauging trading pressure because it matches a prior zero balance and produces an invalid percentage change (“NaN”) and a zero-day short-interest ratio. Adicet Bio short interest report
- Despite the improved forecasts, HC Wainwright still expects significant losses through 2027. Adicet Bio also recently missed quarterly EPS expectations, underscoring that the company has not yet demonstrated consistent financial improvement.
Overall, ACET’s improved analyst loss forecasts are the main potential reason for the recent strength, but the absence of earnings and the company’s dependence on clinical and financing developments limit the bullish impact.